Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 517

1.

Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000.

Boshier A, Wilton LV, Shakir SA.

Eur J Clin Pharmacol. 2003 Dec;59(10):767-73. Epub 2003 Nov 13.

PMID:
14615857
2.

Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study.

Layton D, Clarke A, Wilton LV, Shakir SA.

Osteoporos Int. 2005 May;16(5):490-500. Epub 2004 Aug 7.

PMID:
15309382
4.

Safety profile of orlistat: results of a prescription-event monitoring study.

Acharya NV, Wilton LV, Shakir SA.

Int J Obes (Lond). 2006 Nov;30(11):1645-52. Epub 2006 Mar 21.

PMID:
16552401
5.

The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients.

Hazell L, Cornelius V, Wilton LV, Shakir SA.

BJU Int. 2009 Feb;103(4):506-14. doi: 10.1111/j.1464-410X.2008.08000.x. Epub 2008 Oct 16.

6.

The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.

Perrio MJ, Wilton LV, Shakir SA.

Obesity (Silver Spring). 2007 Nov;15(11):2712-22.

7.

Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.

Barrera BA, Wilton L, Harris S, Shakir SA.

Osteoporos Int. 2005 Dec;16(12):1989-98. Epub 2005 Aug 31.

PMID:
16133643
8.
9.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
10.

Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.

Twaites BR, Wilton LV, Shakir SA.

Drug Saf. 2007;30(5):419-29.

PMID:
17472420
11.

Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study.

Kasliwal R, Wilton LV, Shakir SA.

Drug Saf. 2009;32(6):499-507. doi: 10.2165/00002018-200932060-00006.

PMID:
19459717
12.
13.

The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.

Biswas PN, Wilton LV, Shakir SW.

J Hum Hypertens. 2002 Nov;16(11):795-803.

14.

The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England.

Twaites BR, Wilton LV, Shakir SA.

J Psychopharmacol. 2007 Jun;21(4):392-9. Erratum in: J Psychopharmacol. 2008 Aug;22(6):699. J Psychopharmacol. 2007 Sep;21(7):783.

PMID:
17656426
15.
16.

Safety profile of oxcarbazepine: results from a prescription-event monitoring study.

Buggy Y, Layton D, Fogg C, Shakir SA.

Epilepsia. 2010 May;51(5):818-29. doi: 10.1111/j.1528-1167.2009.02489.x. Epub 2010 Feb 3.

17.
18.

Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.

Twaites B, Wilton LV, Layton D, Shakir SA.

Acta Diabetol. 2007 Dec;44(4):233-9. Epub 2007 Sep 15.

PMID:
17874223
19.
20.

A post-marketing observational study to assess the safety of mibefradil in the community in England.

Riley J, Wilton LV, Shakir SA.

Int J Clin Pharmacol Ther. 2002 Jun;40(6):241-8.

PMID:
12078937

Supplemental Content

Support Center